

JOIN US

in delivering science for better health

**Revistas de ciencias de la salud: publicar y lograr
objetivos con el mínimo esfuerzo**
ENTREPARES, Septiembre 2014
Elena Becker-Barroso

THE LANCET



Objetivos:

- Exito

- Eficiencia

- Estimulo

**JOIN
US**

In delivering science
for better health


THE LANCET

Agenda:

- **Elegir la revista**
- **Superar el peer-review**
- **Alcanzar los objetivos marcados**
- **>Preguntas y debate<**

Elegir la revista

THE LANCET



JOIN
US

In delivering science
for better health

THE LANCET

Elegir la revista: debe guiarme el factor de impacto?

Mark	Rank	Abbreviated Journal Title <i>(linked to journal information)</i>	ISSN		
				Total Cites	Impact Factor
<input type="checkbox"/>	1	LANCET NEUROL	1474-4422	17534	21.823
<input type="checkbox"/>	2	ALZHEIMERS DEMENT	1552-5260	3821	17.472
<input type="checkbox"/>	3	NAT REV NEUROL	1759-4758	3257	14.103
<input type="checkbox"/>	4	ANN NEUROL	0364-5134	33670	11.910
<input type="checkbox"/>	5	BRAIN	0006-8950	44457	10.226
<input type="checkbox"/>	6	ACTA NEUROPATHOL	0001-6322	12284	9.777
<input type="checkbox"/>	7	SLEEP MED REV	1087-0792	3512	9.141
<input type="checkbox"/>	8	NEUROLOGY	0028-3878	76845	8.303
<input type="checkbox"/>	9	NEUROSCIENTIST	1073-8584	3594	7.618
<input type="checkbox"/>	10	ARCH NEUROL-CHICAGO	0003-9942	22121	7.008

Elegir la revista

- **Lancet Neurol (21.82)**
- **Alzheimers&Dement (17.47)**
- **Annals Neurol (11.91)**
- **Brain (10.22)**
- **Neurology (8.30)**
- **JAMA Neurol (7.00)**

Elegir la revista: nunca sin primero leer Information for Authors

“The Lancet publishes a weekly general medical journal and seven monthly specialty journals in the fields of diabetes and endocrinology, global health, infectious diseases, neurology, oncology, psychiatry, and respiratory medicine.”

“The Lancet Neurology considers any original research contribution that advocates change in, or illuminates, neurological clinical practice, and publishes interesting and informative reviews on any topic connected with neurology. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal.”

[Types of article and manuscript requirements](#)

**JOIN
US**

In delivering science
for better health

THE LANCET

The Lancet Neurology

32 Jamestown Road
London NW1 7BY, UK
T +44 (0) 20 7424 4272
F +44 (0) 18 6585 3014
e.becker-barroso@lancet.com

The Lancet—New York

360 Park Avenue South,
New York, NY 10010-1710, USA
T +1 212 633 3810
F +1 212 633 3853

The Lancet—Beijing

Unit 1-6, 7F, Tower W1, Oriental
Plaza, Beijing 100738, China
T + 86 10 85208872
F + 86 10 85189297

www.thelancet.com/neurology

Editor

Elena Becker-Barroso

Deputy Editors

Rebecca Craven
Helen Frankish

Senior Editors

Heather Brown
Steven Goodrick
Rachel Jones
Allison Rowan

Managing Editor

Hannah Jones

Deputy Managing Editor

Laura Benham

Web Editors

Richard Lane
Erika Niesner

Senior Assistant Web Editor

Nicolai Humphreys

Asia Editor

Helena Hui Wang (Beijing)

Conference Editor

Laura Hart

Senior Assistant Editors

Olaya Astudillo
Stephanie Bartlett

Editorial


- 929 High demands of the Autism Centers of Excellence programme

Comment

- 930 Is the door open again for neuroprotection trials in stroke?

 M Kaste

- 931 From genes to stroke subtypes

 P Amouyel

- 933 Microcystic macular oedema in MS: T2 lesion or black hole?

 A Petzold

- 934 Corrections

Correspondence

- 935 The adverse effects of antiepileptic drugs differ in patients with migraine

JA Carpay, MD Ferrari; FG Gilliam, P Perucca

In Context

- 936 Hollywood star leads the way in Parkinson's research

D Mohammadi

- 938 Profile
Marjo van der Knaap: searching for patterns in the chaos

D Holmes

- 939 Ten most wanted

- 939 Lifeline

T N Turan



- 940 Book
A bidirectional approach to depression and neurological disease

T Stevens



- 941 News in brief

Articles



- 942 Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial

  M D Hill and others

- 951 Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies



  M Traylor and others

- 963 Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study

  S Saidha and others

Review

- 973 Megalencephalic leukoencephalopathy with subcortical cysts: chronic white matter oedema due to a defect in brain ion and water homeostasis

  M S van der Knaap and others

- 986 The link between the GBA gene and parkinsonism

E Sidransky, G Lopez

Rapid Review

- 999 Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach

R Baron and others

Personal View

- 1006 Cognitive reserve in ageing and Alzheimer's disease

Y Stern



JOIN US

in delivering science for better health

The Lancet is the world's leading independent general medical journal, delivering essential peer-reviewed content, perspective on important medical advances, groundbreaking clinical reports and candid commentary.

Discover more at: www.thelancet.com

[facebook.com/thelancetmedicaljournal](https://www.facebook.com/thelancetmedicaljournal)

THE LANCET

- Tweets >
- Following >
- Followers >
- Favorites >
- Lists >

Tweet to The Lancet

@TheLancet

Photos and videos >



Who to follow - Refresh - View all

- The Bipolar Project** @Bi... x
Followed by Mind and others
[Follow](#)
- Global Health** @GHJournal x
[Follow](#)
- Shobha Shukla** @shobha1... x



The Lancet
@TheLancet

Welcome to The Lancet on Twitter. Keep in touch with The Lancet, the world's leading general medical journal.

London, New York, Beijing · thelancet.com

TWEETS
2,491

FOLLOWING
58

FOLLOWERS
107K

Following

Followed by Elsevier, ICM, Lancet Student and 55 others.

Tweets

- Retweeted by The Lancet
 GlobalSurgCommission @GSCommission · 18h
We need your input! @GSCommission call for comments. Guide @TheCommission on Global Surgery @ow.ly/u1ub1 #globalsurgery
[Expand](#) [Reply](#) [Retweet](#) [Favorite](#)
- Retweeted by The Lancet
 Academy of Med Sci @acmedsci · 18h
.@Richardhorton1 introduces the Young Investigator plenary competition #AMSSpring meeting ow.ly/i/4IKZj
[View photo](#) [Reply](#) [Retweet](#) [Favorite](#)

Superar el peer-review

- Information for authors
 - <http://www.thelancet.com/lancet-neurology-information-for-authors/article-types-manuscript-requirements>
- Reporting guidelines:
 - <http://www.equator-network.org>
- Contact the editors


STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-6

Superar el peer-review: la importancia de una buena “cover letter”



VS




**JOIN
US**

In delivering science
for better health

THE LANCET

Superar el peer-review



JOIN
US

In delivering science
for better health

THE LANCET

Superar el peer-review

“Progress in science is determined at two levels: funding and publication.

[....] Peer review is the basis for any progress in science.”

Cell, 2006; 126: 637-38



Superar el peer-review

- What kind of evaluation?
- Design and methodology
- Quality of the data
- **Originality**
- **Relevance**
- How is the evaluation done?
- **Single blind**
- **Time frame**
- **Decision-making**
- **Otras consideraciones**

Fast-track peer review en *Lancet*



The editorial meeting



**JOIN
US**

In delivering science
for better health

THE LANCET

Age-specific population frequencies of cerebral β -amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study



Clifford R Jack Jr, Heather J Wiste, Stephen D Weigand, Walter A Rocca, David S Knopman, Michelle M Mielke, Val J Lowe, Matthew L Senjem, Jeffrey L Gunter, Gregory M Preboske, Vernon S Pankratz, Prashanthi Vemuri, Ronald C Petersen

Summary

Background As preclinical Alzheimer's disease becomes a target for therapeutic intervention, the overlap between imaging abnormalities associated with typical ageing and those associated with Alzheimer's disease needs to be recognised. We aimed to characterise how typical ageing and preclinical Alzheimer's disease overlap in terms of β -amyloidosis and neurodegeneration.

Methods We measured age-specific frequencies of amyloidosis and neurodegeneration in individuals with normal cognitive function aged 50–89 years. Potential participants were randomly selected from the Olmsted County (MN, USA) population-based study of cognitive ageing and invited to participate in cognitive and imaging assessments. To be eligible for inclusion, individuals must have been judged clinically to have no cognitive impairment and have undergone amyloid PET, ^{18}F -fluorodeoxyglucose (^{18}F -FDG) PET, and MRI. Imaging results were obtained from March 28, 2006, to Dec 3, 2013. Amyloid status (positive [A+] or negative [A-]) was determined by amyloid PET with ^{11}C Pittsburgh compound B. Neurodegeneration status (positive [N+] or negative [N-]) was determined by an Alzheimer's disease signature ^{18}F -FDG PET or hippocampal volume on MRI. We determined age-specific frequencies of the four groups (amyloid negative and neurodegeneration negative [A-N-], amyloid positive and neurodegeneration negative [A+N-], amyloid negative and neurodegeneration positive [A-N+], or amyloid positive and neurodegeneration positive [A+N+]) cross-sectionally using multinomial regression models. We also investigated associations of group frequencies with *APOE* $\epsilon 4$ status (assessed with DNA extracted from blood) and sex by including these covariates in the multinomial models.

Findings The study population consisted of 985 eligible participants. The population frequency of A-N- was 100% (n=985) at age 50 years and fell to 17% (95% CI 11–24) by age 89 years. The frequency of A-N- increased to 28% (24–32) at age 74 years, then decreased to 17% (11–25) by age 89 years. The frequency of A-N+ increased from age 60 years, reaching 24% (16–34) by age 89 years. The frequency of A+N- increased from age 65 years, reaching 42% (31–52) by age 89 years. The results from our multinomial models suggest that A-N+ and A+N- were more frequent in *APOE* $\epsilon 4$ carriers than in non-carriers and that A-N+ was more, and A+N- less frequent in men than in women.

Interpretation Accumulation of amyloid and neurodegeneration are nearly inevitable by old age, but many people are able to maintain normal cognitive function despite these imaging abnormalities. Changes in the frequency of amyloidosis and neurodegeneration with age, which seem to be modified by *APOE* $\epsilon 4$ and sex, suggest that pathophysiological sequences might differ between individuals.

Funding US National Institute on Aging and Alexander Family Professorship of Alzheimer's Disease Research.

Lancet Neurol 2014;
13: 997–1005

Published Online
September 5, 2014
[http://dx.doi.org/10.1016/S1474-4422\(14\)70194-2](http://dx.doi.org/10.1016/S1474-4422(14)70194-2)

See Comment page 965

Department of Radiology

(Prof C R Jack Jr MD,
Prof V J Lowe MD,
M L Senjem MS, J L Gunter PhD,
G M Preboske MS,
P Vemuri PhD), Department of
Health Sciences Research
(H J Wiste BA, S D Weigand MS,
Prof W A Rocca MD,
M M Mielke PhD,
V S Pankratz PhD), and
Department of Neurology
(W A Rocca,
Prof D S Knopman MD,
Prof R C Petersen MD), Mayo
Clinic and Foundation,
Rochester, MN, USA

Correspondence to:
Prof Clifford R Jack Jr,
Department of Radiology, Mayo
Clinic and Foundation,
Rochester, MN 55905, USA
jack.clifford@mayo.edu

Agenda:

- **Elegir la revista**
- **Superar el peer-review**
- **Alcanzar los objetivos marcados**
- **>Preguntas y debate<**

JOIN US

in delivering science for better health

Preguntas?

THE LANCET